Prevention of CVD - From Epidemiology to Guidelines and Policies


Dr Pamela Morris, USA    04 January 2018

  1. The 2017 focused update of 2016 ACC EDCP address four statin benefit groups: Adults ≥21 years of age with clinical ASCVD on statin for secondary prevention; or with LDL-C ≥190 mg/dL on statin for primary prevention; adults aged 45-70 years without ASCVD but with diabetes and LDL-C 70-189 mg/dL on statin for primary prevention; or without clinical ASCVD or diabetes, with LDL-C 70-189 mg/dL and an estimated 10-year risk for ASCVD of ≥7.5% on statin for primary prevention.
  2. LAI 2016: Nonstatin drugs are recommended to be used in case of complete statin intolerance; first-line therapy when TG >500 mg/dL; in combination with statins when desired statin dose is not tolerated or in persistent hypertriglyceridemia.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.